(LCTX) |
|
0 (0%)
|
09-28 20:34 |
|
Open: |
|
Pre. Close: |
|
|
High:
|
|
Low:
|
|
|
Volume:
|
0 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2023-09-28 4:51:45 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.53 One year: 1.65 |
| Support: |
Support1: 1.14 Support2: 0.95 |
| Resistance: |
Resistance1: 1.31 Resistance2: 1.41 |
| Pivot: |
1.26 |
| Moving Average: |
MA(5): 1.17 MA(20): 1.28
MA(100): 1.36 MA(250): 1.34  |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 11.1 %D(3): 10.1 |
| RSI: |
RSI(14): 31.5 |
| 52-week: |
High: 1.58 Low: 1.01 |
| Average Vol(K): |
3-Month: 449 (K) 10-Days: 597 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LCTX ] has closed above bottom band by 13.5%. Bollinger Bands are 51.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.2 - 1.21 |
1.21 - 1.22 |
|
Low:
|
1.13 - 1.14 |
1.14 - 1.15 |
|
Close:
|
1.16 - 1.17 |
1.17 - 1.18 |
|
Company Description |
|
|
Headline News |
Tue, 19 Sep 2023
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare ... - Business Wire
Fri, 15 Sep 2023
Is Lineage Cell Therapeutics Inc (LCTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Mon, 11 Sep 2023
Lineage to Present at 2023 International Spinal Research Trust ... - Business Wire
Wed, 06 Sep 2023
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics - Yahoo Finance
Sun, 13 Aug 2023
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2023 Earnings Call Transcript - Yahoo Finance
Thu, 10 Aug 2023
Lineage Cell Therapeutics Reports Second Quarter 2023 Financial ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: |
| Sector: |
| Industry: |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
